Treasury & Bonds
View Full List
500 Stocks Estimate
NYSE COMPOSITE INDX
Add to My Watchlist
Price and Volume
N/A - N/A
N/A - N/A
Key U.S. Dry Eye Patent Issued to RegeneRx
February 22, 2018
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the...
RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage
February 14, 2018
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the...
RegeneRx Releases Annual Letter to Shareholders
December 07, 2017
T?4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium
November 16, 2017
RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial
October 31, 2017
RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S.
September 13, 2017
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
August 31, 2017
RegeneRx Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York September 10-12, 2017
August 30, 2017
RegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy
August 14, 2017
RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial
July 27, 2017
RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy
June 13, 2017
Stock Market JSON API
provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial